Achaogen’s Plazomicin Development Program Saved By FDA Faith In Limited Use
This article was originally published in The Pink Sheet Daily
Executive Summary
After struggling to enroll a trial targeting carbapenem-resistant Enterobacteriaceae, Achaogen will now target complicated urinary tract infection as the first indication for plazomicin.
You may also be interested in...
Plazomicin's BSI Indication Could Be First LPAD Drug – If Achaogen Can Convince US FDA Of Efficacy
Advisory committee will review applications for cUTI indication, which looks good, and the BSI indication, which looks fraught.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.